GIP
Coverage of GIP in the Nexus archive.
- BlackRock's M&A spree comes into clear view
BlackRock is raising $12 billion for a Texas data center occupied by Meta, marking its first major collaboration between GIP and HPS since acquiring them in 2024 and 2025. CEO Larry Fink highlighted accelerating integration of BlackRock, HPS, and GIP in deal origination, reducing reliance on banks like JPMorgan and Morgan Stanley. A conflict at Aston Martin involves opposing sides within BlackRock.
- Brookfield, GIP Defy War to Advance $7.5 Billion Kuwait Deal
Brookfield and GIP are proceeding with a $7.5 billion deal in Kuwait despite ongoing war conditions. The deal involves Kuwait Petroleum Corp., led by Sheikh Nawaf Al-Sabah.
- Weekly diabetes jab shown to reduce blood-sugar levels and body weight
A new triple-action weekly jab for type 2 diabetes, retatrutide, showed significant reductions in blood sugar and body weight in phase 3 trials. Patients receiving retatrutide lost over four times more weight and experienced more than twice the drop in HbA1c compared to placebo. The drug mimics three gut hormones (GLP-1, GIP, and glucagon) and differs from existing diabetes medications by engaging the glucagon receptor to increase energy expenditure.
- Lilly’s new experimental shot produced 28% weight loss
Eli Lilly has developed an experimental weight loss injection that achieved 28% weight loss in trials. The new shot differs from existing medications Zepbound and Foundayo by combining three active components: GIP, GLP-1, and glucagon.
- Abu Dhabi’s L’imad Eyes $30 Billion Infra Push With Temasek, GIP
Abu Dhabi's L'imad is planning a $30 billion infrastructure push in collaboration with Temasek and GIP. This investment aims to boost development in the region. The project involves residential high-rise buildings in Abu Dhabi.
- New “Trojan horse” obesity drug supercharges weight loss in early tests
Researchers have created a new obesity drug that uses GLP-1/GIP signals to target cells and enhance metabolism, outperforming existing treatments in mice by curbing appetite and improving blood sugar levels. The drug can be used at lower doses, potentially reducing side effects. It shows promise for effective weight loss.